May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Clinical and Immunehistochemical Findings After Heavy Internal Tamponade With Oxane HD®
Author Affiliations & Notes
  • N. Stupp
    Eye Clinic, University Muenster, Munster, Germany
  • H. Herbst
    Vivantes Clinic Neukölln, Department of Pathology, Berlin, Germany
  • H. Gerding
    Eye department, Klinik Pallas, Olten, Switzerland
  • Footnotes
    Commercial Relationships  N. Stupp, None; H. Herbst, None; H. Gerding, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5505. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. Stupp, H. Herbst, H. Gerding; Clinical and Immunehistochemical Findings After Heavy Internal Tamponade With Oxane HD® . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5505.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: 1. To evaluate the anatomical results, functional outcome, and ocular complications of heavy internal tamponade applying Oxane HD® and 2. to describe and characterize secondary proliferations occurring in reaction to this new substance by immunehistochemical techniques. Methods: Oxane HD® was applied in 24 patients (24 eyes, f =11, m =13, median age 60.5 years, range 40– 84 years) with complicated retinal detachment involving significantly the inferior part of the retina between July 1st 2003 and February 28th, 2004. 13/24 eyes had one or more previous unsuccessful major retinal/vitreoretinal interventions. Basic pathology: PVR 16 (mainly stage C3 – D2), PDVR 4, traumatic PVR 2, others 2. Oxane HD® was removed after 40– 264 days (median 110 days). The prospective protocol included follow–up examinations at 1, 3, 6 months, and 1 year after Oxane HD® application. Newly formed epiretinal tissue excised at reintervention or Oxane HD® removal was stained with HE and following immunehistochemical markers: CD31, CD68, CD45, GFAP, vimentin, MIB1, MNF116 and S–100. Results: Complete retinal attachment was primarily achieved in 20/24 eyes. 7 eyes needed reintervention due to tractive redetachment (6 inferior, 1 superior). At the end of follow up 18/21 eyes showed total retinal attachment, 3/21 partial peripheral detachment. Functional results: improved visual acuity (at least 2 LogMar lines): 16, unchanged 4, deterioration 4. None of the eyes showed significant dispersion in the posterior segment. 6/24 presented relative small dispersion in the anterior chamber. During and after the application of Oxane HD® ocular hypertension (>25mmHg) occurred in 3/20, permanent hypotony in 1/20 (successfully elevated by intravitreal triamcinolone). Profound proliferative reaction in form of membrane development was found in 11/24 eyes. 6 of these membranes included clinically detectable neovascularisation. The majority of excised membranes presented significant staining for CD31 (23/26 specims), GFAP (25/26), vimentin (25/26), and CD45 (25/26). Conclusions: Oxane HD® was uncomplicated concerning secondary effects like dispersion, hypertension and hypotony. During the periode of internal tamponade a relatively high rate of extensive secondary membrane proliferations and tractional redetachments occurred. Immunhistological results indicate that membrane proliferation seems to be significantly accompanied by three main components, namely glial proliferation, angiogenesis and lymphocytic reaction.

Keywords: retinal detachment • vitreoretinal surgery • vitreous substitutes 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.